Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Accurate Diagnosis of Functional Motor Disorders in Elders Critical to Long-Term Care, Management
December 21st 2023The research aimed to assess FMD prevalence and clinical manifestations in both elderly and younger onset individuals, revealing insights into symptom variations across different age groups.
NeuroVoices: Ponni Subbiah, MD, MPH, on the Open-Label LILAC-2 Study of Trofinetide
December 20th 2023The senior vice president, global head of medical affairs, and chief medical officer at Acadia Pharmaceutical, gave an overview of LILAC-2, a long-term extension study assessing trofinetide (Daybue), the first approved therapy for Rett syndrome.
Quantifying Impact of Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders
December 19th 2023Elizabeth M. Cassidy, MPH, research project manager at the TSC Alliance, provided clarity on a presentation at AES 2023 examining the association between TSC-associated neuropsychiatric disorders and seizure duration.
Real-Time Quaking-Induced Conversion CSF Analysis Useful in Detecting Misfolded Alpha-Synuclein
December 18th 2023A-synuclein-positive athletes were similar to α-synuclein-negative athletes on demographics and other serum and blood biomarkers; however, these patients had lower grey matter volumes in the right inferior orbitofrontal, right anterior insula, and right olfactory cortices.
NeuroVoices: Irfan Qureshi, MD, on the Therapeutic Potential of Antiseizure Agent BHV-7000
December 13th 2023The chief medical officer of Biohaven discussed early-stage data supporting the efficacy and safety of BHV-7000, a selective Kv7.2/7.3 potassium channel activator in development for patients with epilepsy.
Nerivio REN Device Results in Reduced Treatment Days for Adolescents With Migraine
December 12th 2023The frequent use of REN wearable device for the acute treatment of migraine was shown to reduce the number of monthly treatments in adolescents, with a similar reduction in migraine and headache days seen in a pivotal prevention trial in adults.
Greater Insights on Skyhawk’s RNA Splicing Agent SKY-0515 for Huntington Disease
December 11th 2023Maura McCarthy, head of corporate development at Skyhawk Therapeutics, provided comment on a new phase 1 study assessing SKY-0515, a small molecule candidate as a potential treatment for Huntington disease.
Phase 3 Findings Demonstrate Impacts of NE3017 in Alzheimer Cognition, Function
December 8th 2023Using outcomes such as the CDR-SB, ADAS-Cog12, MMSE, and ADCOMS, patients treated with NE3017 for 6 months demonstrated equal, if not greater, improvements than traditional antiamyloid therapies at 18 months.
Open-Label LILAC-2 Data Demonstrates Trofinetide’s Long-Term Treatment Benefit in Rett Syndrome
December 7th 2023Over a 32-week treatment period, patients on trofinetide continued to show improvements on the primary efficacy outcomes of Rett Syndrome Behavior Questionnaire and Clinical Global Impression-Improvement total scores.
NeuroVoices: Cathleen Lutz, PhD, on the Potential of Stathmin-2 as an ALS-Specific Biomarker
December 6th 2023The vice president of the Rare Disease Translational Center at the Jackson Laboratory provided context on a recently published study suggesting restoration of stathmin-2 as a therapeutic approach for ALS.